Merck licenses Chinese cancer drug, searching for next Keytruda blockbuster
In a move to safeguard the company’s dominant position in cancer, Merck said Thursday it will license a new cancer drug from LaNova Medicines, a Shanghai-based firm, for $588 million upfront and as much as $2.7 billion in potential milestone payments.
The company is paying China-based biotech LaNova Medicines $588 million for the kind of dual-pronged antibody drug that ...
(Yicai) Nov. 15 -- The Germany’ Merck and five other overseas pharmaceutical companies have been given the green light to ...
Merck KGaA (MRCG.DE), opens new tab on Thursday reported a gain of 11.9% in adjusted quarterly earnings, helped by ...
Merck & Co. is paying $588 million upfront to defend its Keytruda kingdom. The outlay, plus up to $2.7 billion in milestones, ...
As the rollout of its recently launched pulmonary arterial hypertension (PAH) drug Winrevair ramps up, Merck is continuing ...
We recently compiled a list of the 10 Best Pharma Stocks To Buy Right Now. In this article, we are going to take a look at ...
Merck's undervalued stock presents growth opportunities with Keytruda and promising pipeline drugs, making it a Buy despite ...
This health news summary explores various pharmaceutical developments including Novo Nordisk's phasing out of insulin pens, a ...
Merck is playing defense against Summit Therapeutics with a $3.3 billion licensing deal announced Thursday for a cancer drug.
Results that may be inaccessible to you are currently showing.
Hide inaccessible results
Feedback